Revisions for Efficacy and safety of the monoclonal antibody nimotuzumab plus FOLFOX vs. FOLFOX as first-line treatment of patients with unresectable, left-sided, metastatic colorectal cancer. Phase I/II | Registro Público Cubano de Ensayos Clínicos

The revisions let you track differences between multiple versions of a post.

To edit, publish or delete one of the revisions below, click on its saved date.

Published clinical_trials Efficacy and safety of the monoclonal antibody nimotuzumab plus FOLFOX vs. FOLFOX as first-line treatment of patients with unresectable, left-sided, metastatic colorectal cancer. Phase I/II has only one revision

Registered Trials

Registration process

About the RPCEC

Useful resources